Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | Chief Financial Officer | March 26, 2026 | March 28, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Chief Financial Officer | February 23, 2021 | February 25, 2021 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date March 26, 2026 · Filed March 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 152,002 |
Reported balance
After 2026-03-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-26 · Grant · Acquired 75,000 · Balance 152,002 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 26, 2027. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.64 · Expires 2036-03-25 | Direct | 157,635 |
Reported balance
After 2026-03-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-26 · Grant · Acquired 157,635 · Balance 157,635 F3: The share option shall vest in forty-eight equal monthly installments beginning on April 26, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 26, 2027.
F3: The share option shall vest in forty-eight equal monthly installments beginning on April 26, 2026.
SQZ Biotechnologies Co
Report date February 23, 2021 · Filed February 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.85 · Expires 2031-02-22 | Direct | 75,950 |
Reported balance
After 2021-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-23 · Grant · Acquired 75,950 · Balance 75,950 F1: The option vests and becomes exercisable as to 25% of the underlying securities on February 23, 2022 and in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 25% of the underlying securities on February 23, 2022 and in 36 substantially equal monthly installments thereafter.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 12,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control . |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control .
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001829111-26-000009 · wk-form4_1781641036.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001829111-26-000009 · wk-form4_1781641036.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,481 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control . Read SEC document |
| March 26, 2026 Filed Mar 28, 2026 01:52 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 157,635 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001829111-26-000007 · wk-form4_1774662750.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,635 Underlying: Ordinary Shares · 157,635 shares Expires 2036-03-25 F3 · derivative.exercise_date: The share option shall vest in forty-eight equal monthly installments beginning on April 26, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 26, 2026 Filed Mar 28, 2026 01:52 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantOrdinary Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001829111-26-000007 · wk-form4_1774662750.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,002 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 26, 2027. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 21:03 UTC | COMPASS Pathways plc CMPS · Entity 4567 | Tax withholdingOrdinary Shares | 1,781 | $6.89 | $12,271.09 |
DisclosureSEC source: 0001829111-26-000004 · wk-form4_1773435787.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,002 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:58 UTC | COMPASS Pathways plc CMPS · Entity 4567 | Tax withholdingOrdinary Shares | 4,467 | $7.02 | $31,358.34 |
DisclosureSEC source: 0001829111-26-000002 · wk-form4_1772585901.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,783 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001829111-25-000002 · wk-form4_1750111806.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001829111-25-000002 · wk-form4_1750111806.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,216 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 12:15 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001816590-25-000025 · wk-form4_1741868121.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Ordinary Shares · 76,000 shares Expires 2035-03-10 F3 · derivative.exercise_date: The share option shall vest in forty-eight equal monthly installments beginning on April 11, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 12:15 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantOrdinary Shares | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001816590-25-000025 · wk-form4_1741868121.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,250 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 11, 2026. F2 · price: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 11, 2026. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:54 UTC | COMPASS Pathways plc CMPS · Entity 4567 | Tax withholdingOrdinary Shares | 4,468 | $3.67 | $16,397.56 |
DisclosureSEC source: 0001816590-25-000020 · wk-form4_1741128876.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,250 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · derivative · entry 10 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2032-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 529 | $88.54 | $46,835.54 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 9 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,175 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $87.915 to $88.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,013 | $87.38 | $88,512.90 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 8 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,704 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $86.89 to $87.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 966 | $86.26 | $83,324.26 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 7 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,717 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.89 to $86.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,043 | $85.29 | $88,960.60 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 6 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,683 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $84.83 to $85.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,202 | $83.93 | $100,885.06 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 5 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,726 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $83.51 to $84.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,136 | $82.89 | $94,167.58 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 4 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,928 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $82.455 to $83.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 215 | $81.53 | $17,529.81 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 3 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,064 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $81.36 to $81.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 146 | $80.46 | $11,747.16 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,279 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $80.32 to $80.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 6,250 | $22.70 | $141,875.00 |
DisclosureSEC source: 0001649094-25-000006 · wk-form4_1737147935.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · derivative · entry 6 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2032-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 256 | $117.51 | $30,082.56 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · nonDerivative · entry 5 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,175 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,308 | $116.62 | $502,386.90 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · nonDerivative · entry 4 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,431 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $116.25 to $117.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,445 | $115.32 | $166,633.93 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · nonDerivative · entry 3 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,739 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $115.04 to $115.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 241 | $114.64 | $27,627.57 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · nonDerivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,184 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.93 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 6,250 | $22.70 | $141,875.00 |
DisclosureSEC source: 0001649094-24-000069 · wk-form4_1726691078.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000014 · wk-form4_1718050286.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000014 · wk-form4_1718050286.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,175 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:06 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 117,643 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001816590-24-000048 · wk-form4_1709676354.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,643 Underlying: Ordinary Shares · 117,643 shares Expires 2034-02-28 F3 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on March 1, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:06 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantOrdinary Shares | 62,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001816590-24-000048 · wk-form4_1709676354.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,718 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on March 1, 2025. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037505 · doc4.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037505 · doc4.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-22-034066 · doc4.xml · derivative · entry 2 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034066 · doc4.xml · nonDerivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 00:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $26.37 | $0.00 |
DisclosureSEC source: 0001209191-21-056967 · doc4.xml · derivative · entry 1 Loxam Teri · CIK 0001829111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-09-15 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on September 16, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 17:50 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 75,950 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0000899243-21-008256 · doc4.xml · derivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,950 Underlying: Common Stock · 75,950 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying securities on February 23, 2022 and in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 18:31 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 10,530 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029983 · doc4.xml · derivative · entry 1 Loxam Teri · CIK 0001829111 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,530 Underlying: Common Stock · 10,530 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on October 29, 2021 and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.